Wealth Enhancement Trust Services’s Neurocrine Biosciences NBIX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26K	Buy	+154	New	+$22.8K	﹤0.01%	583

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Trust Services's NBIX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 154 shares worth $26K. The stake represents ﹤0.01% of the portfolio and ranks #583 among its holdings.

591 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Wealth Enhancement Trust Services held 154 shares of Neurocrine Biosciences worth $26K as of Q2 2026.
Neurocrine Biosciences was a new Wealth Enhancement Trust Services position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #583 holding.
591 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.